Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Inclusion Criteria:

* Histologically or cytologically confirmed gastric or gastroesophageal junction (GEJ) adenocarcinoma

  * Metastatic or unresectable disease
  * Siewert's classification I, II, or III
* No ulcerated, non-healing tumors or tumors that have developed a malignant fistula
* No esophageal tumors
* No known or active brain metastases
* Performance status - Karnofsky 60-100%
* Performance status - ECOG 0-2
* Neutrophil count \>= 1,500/mm\^3
* Platelet count \>= 75,000/mm\^3
* No bleeding diathesis or coagulopathy
* Bilirubin =\< 1.5 mg/dL
* AST and ALT =\< 3 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
* PT (INR) =\< 1.5
* PTT =\< 3 seconds above ULN
* Creatinine =\< 1.5 mg/dL
* Proteinuria \< 1+
* Protein \< 500 mg/24-hour urine collection
* No acute ischemia or significant conduction abnormality by EKG
* No clinically significant cardiovascular disease
* No uncontrolled hypertension (blood pressure \> 160/90 mm Hg on medication)
* No myocardial infarction within the past 6 months
* No unstable angina within the past 6 months
* No transient ischemic attack within the past 6 months
* No cerebrovascular accident within the past 6 months
* No other arterial thromboembolic event within the past 6 months
* No New York Heart Association class II-IV congestive heart failure
* No serious cardiac dysrhythmia requiring medication
* No peripheral vascular disease (grade II or greater)
* No history of stroke
* No CNS disease within the past 5 years (e.g., uncontrolled seizures)
* No other concurrent uncontrolled illness
* No ongoing or active infection requiring parental antibiotics on Day 0 of study
* No serious, non-healing wound
* No serious wound healing by secondary intention
* No ulcer
* No bone fracture
* No psychiatric illness or social situation that would preclude study compliance
* No significant traumatic injury within the past 28 days
* No other neoplastic disease within the past 3 years except basal cell skin cancer, carcinoma in situ of the cervix, or nonmetastatic prostate cancer
* No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
* No other medical condition that would preclude study participation
* Not pregnant or nursing

  * No nursing during and for 4 months after study participation
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 4 months after study participation
* More than 8 weeks since prior immunotherapy and recovered
* No other concurrent biologic or immunologic agents
* No other concurrent bevacizumab
* No prior chemotherapy for metastatic disease
* No prior cisplatin or irinotecan
* Prior neoadjuvant and/or adjuvant chemotherapy or chemoradiotherapy allowed
* More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
* No other concurrent chemotherapy
* More than 3 weeks since prior radiotherapy and recovered
* No concurrent radiotherapy
* More than 28 days since prior major surgical procedure or open biopsy
* More than 7 days since prior fine needle aspirations or core biopsies
* No concurrent major surgery
* No other concurrent investigational agents
* No other concurrent anticancer therapy
* No concurrent chronic daily aspirin (\> 325 mg/day)
* No concurrent nonsteroidal anti-inflammatory medications that would inhibit platelet function at doses used to treat chronic inflammatory diseases
* Full-dose anticoagulants allowed, provided the following criteria are met:

  * INR in range (i.e., 2-3) while on a stable dose of warfarin or low molecular weight heparin
  * No active bleeding or pathologic condition that would confer a high risk of bleeding (e.g., tumor involving major blood vessels or known varices)
* No concurrent thrombolytic agents
* No concurrent vitamins, antioxidants, herbal preparations, or supplements

  * Single tablet multivitamin allowed